A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours
Open Access
- 27 May 2008
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 98 (11) , 1762-1768
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular featuresAnnals of Oncology, 2007
- Gastrointestinal stromal tumourThe Lancet, 2007
- 31st Annual Scientific Meeting, Australasian Division of the International Academy of PathologyPathology International, 2006
- Clinical, Pathologic, and Immunohistochemical Characteristics of Gastrointestinal Stromal Tumors of the Colon and Rectum: Implications for Surgical Management and Adjuvant TherapiesDiseases of the Colon & Rectum, 2006
- Current Incidence and Outcomes of Gastrointestinal Mesenchymal Tumors Including Gastrointestinal Stromal TumorsJournal of the American College of Surgeons, 2006
- Pathology of gastrointestinal stromal tumorsPathology International, 2006
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal TumorNew England Journal of Medicine, 2001
- Etude de clones derivés d'une lignée cellulaire chroniquement infectée par le virus de RauscherEuropean Journal of Cancer (1965), 1967